ReviewDrug delivery and translational research2020
Recent technological advancements in stem cell research for targeted therapeutics.
Review in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering.International journal of molecular sciences · 2026Review
- A Review of Therapeutic Strategies to Enhance ;Neuroplasticity in Parkinson's Disease: ;Implications for Slowing Disease Progression ;and Promoting Recovery.Annals of neurosciences · 2026Review
- Characteristics of the Stem Cell Intellectual Property Rights and Patent Status: Focusing on Papers and Clinical Trials.Development & reproduction · 2026Article
- Review
- Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics.Bioengineering (Basel, Switzerland) · 2023Review
- Suspension culture strategies to enrich colon cancer stem cells.Oncology letters · 2023Article
- Ethyl Acetate Extract ofACS omega · 2023Article
- Stem Cell Therapy, the Market, the Opportunities and the Threat.International journal of molecular and cellular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Stem cells have characteristic features of self-renewal, pluripotency and differentiation, which are responsible for replenishment of tissue or organ. Stem cells are potentiated as therapeutic tool in drug targeting and regenerative medicine-from curing various neurological diseases and malignancies to congenital diseases. These technological advancements have established stem cells as future of medicine. However, due to ethico-social limitations, the use of embryonic stem cells (ESCs) has been avoided, while physiological availability of adult stem cells (ASCs) and induced pluripotent stem cells (iPSCs) has gained appropriate preference. These iPSCs are very much similar to ESCs in terms of their self-renewal and pluripotency. Here, we have summarized the technologies that have established stem cells isolation, their molecular marker and factors responsible for their maintenance. Different cellular (transcription factors, regulatory proteins, miRNA like miRNA-296, miRNA-145, etc.) and extracellular components transcend stem cell fate. Their identification and characterization involve development and efficient utilization of tools like magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS). Some of the technologies have been patented and spin-off's based on them have been commercialized. In conclusion, we present the future scope and possibilities that stem cell technologies behold for us. Graphical abstract Pictorial representation of therapeutic approaches for disease treatment using stem cell technology. Disease-specific adult stem cells are isolated along with niche cells by utilizing tools like FACS/MACS/LCM, etc. Thereafter, cells are reprogrammed through introduction of Yamanaka factors (Oct3/4, Sox2, c-myc, Klf4) to make induced pluripotent stem cell (iPSCs). The disease-specific iPSCs undergo genetic modification after delivery of therapeutic gene through retroviral vehicle. The genetically modified cells are introduced back in person with disease for therapeutic effects. FACS, fluorescence activated cell sorting; MACS, magnetic-activated cell sorting; LCM, laser capture microdissection; Oct3/4, octamer-binding transcription factor 3/4; Sox2, sex determining region Y-box 2; Klf4, Kruppel-like factor 4.
Indexed as
Identifiers
32410157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.